Breaking News Instant updates and real-time market news.

PFE

Pfizer

$33.56

-0.09 (-0.27%)

, MRK

Merck

$62.77

0.11 (0.18%)

18:10
10/09/16
10/09
18:10
10/09/16
18:10

Pfizer reports data on Inlyta-Keytruda, Inlyta-avelumab studies

Pfizer (PFE) announced data from an ongoing, investigational Phase 1b study of INLYTA combined with the checkpoint inhibitor pembrolizumab, a PD-1 inhibitor known as KEYTRUDA and marketed by Merck (MRK), in treatment-naive patients with advanced renal cell carcinoma. Preliminary results from a similar, separate study combining INLYTA with avelumab, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody that is being co-developed by Merck KGaA (MKGAY) and Pfizer were also presented. The data suggest evidence of anti-tumor activity for INLYTA in combination with avelumab. Based on these Phase 1 results, two independent global Phase 3 trials evaluating these combinations - INLYTA plus pembrolizumab and INLYTA plus avelumab - each compared with SUTENT in first-line advanced RCC are now enrolling patients. Specifically, early indicators from the A4061079 study point to strong response rates with the INLYTA/pembrolizumab combination, with 37 patients achieving objective responses, including three complete responses and 34 partial responses. 10 patients had stable disease and 5 patients had disease progression. Separately, in the JAVELIN Renal 100 study of INLYTA in combination with avelumab, five out of six patients treated so far had confirmed partial responses -- objective response rate 83.3% -- and one patient with tumor shrinkage not meeting partial response criteria had stable disease.

PFE

Pfizer

$33.56

-0.09 (-0.27%)

MRK

Merck

$62.77

0.11 (0.18%)

MKGAY

Merck KGaA

$35.88

0.1 (0.28%)

  • 25

    Oct

  • 01

    Nov

  • 06

    Nov

PFE Pfizer
$33.56

-0.09 (-0.27%)

08/23/16
PIPR
08/23/16
NO CHANGE
PIPR
Pfizer acquisition 'a good fit strategically,' says Piper Jaffray
After Pfizer (PFE) agreed to buy Medivation (MDVN), Piper Jaffray analyst Richard Purkiss says that Pfizer has obtained Xtandi, "a blockbuster prostate cancer treatment," and "a close-to-market and late-stage pipeline." The analyst thinks that Xtandi's expansion to use in adjuvant prostate cancer could increase its sales by 65%-70%. He keeps a $54 price target and Overweight rating on Pfizer.
08/23/16
RHCO
08/23/16
DOWNGRADE
RHCO
Neutral
Medivation downgraded to Neutral from Buy at SunTrust
Medivation (MDVN) has agreed to be acquired by Pfizer (PFE) for $81.50 per share.
09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
10/07/16
ROTH
10/07/16
NO CHANGE
Target $160
ROTH
Buy
ICU Medical price target raised to $160 from $132 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for ICU Medical (ICUI) to $160 from $132 after the company announced an agreement to acquire Hospira Infusion Systems from Pfizer (PFE) for $1B. The analyst is overall positive on the deal as it removes the long-standing customer concentration overhang and grows ICU Medical into a legitimate pure-play infusion therapy company with a complete product portfolio. The company also preannounced Q3 preliminary results above expectations, he notes. Lewis reiterates a Buy rating on ICU Medical's shares.
MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.
MKGAY Merck KGaA
$35.88

0.1 (0.28%)

08/12/16
BREN
08/12/16
DOWNGRADE
BREN
Hold
Merck KGaA downgraded to Hold from Buy at Berenberg

TODAY'S FREE FLY STORIES

DE

Deere

$167.54

-1.76 (-1.04%)

08:06
01/17/18
01/17
08:06
01/17/18
08:06
Recommendations
Deere analyst commentary  »

Deere price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

RIOT

Riot Blockchain

$18.28

-3.6 (-16.45%)

08:05
01/17/18
01/17
08:05
01/17/18
08:05
Hot Stocks
Riot Blockchain's Tess Pay signs agreement for Cresval Capital transaction »

Riot Blockchain's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

WAFD

Washington Federal

$35.60

-0.05 (-0.14%)

08:05
01/17/18
01/17
08:05
01/17/18
08:05
Earnings
Washington Federal reports Q4 EPS 59c, consensus 51c »

Return on equity for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICHR

Ichor Holdings

$25.60

0.86 (3.48%)

08:05
01/17/18
01/17
08:05
01/17/18
08:05
Earnings
Ichor Holdings sees Q1 revenue $240M-$250M, consensus $208.35M »

For 1Q18, Ichor expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

OBE

Obsidian Energy

08:04
01/17/18
01/17
08:04
01/17/18
08:04
Hot Stocks
FrontFour Capital voices concerns regarding Obsidian Energy »

FrontFour Capital Group,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$54.90

0.07 (0.13%)

08:04
01/17/18
01/17
08:04
01/17/18
08:04
Downgrade
HSBC rating change  »

HSBC downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICHR

Ichor Holdings

$25.60

0.86 (3.48%)

08:04
01/17/18
01/17
08:04
01/17/18
08:04
Earnings
Ichor Holdings sees Q4 revenue $183M, consensus $181.17M »

Ichor Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

RGC

Regal Entertainment

$22.90

-0.07 (-0.30%)

08:03
01/17/18
01/17
08:03
01/17/18
08:03
Downgrade
Regal Entertainment rating change  »

Regal Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.55 (-2.93%)

08:03
01/17/18
01/17
08:03
01/17/18
08:03
Hot Stocks
GE Transportation signs locomotive, service agreements valued at over $900M »

GE Transportation signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DWDP

DowDuPont

$74.95

-0.46 (-0.61%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Hot Stocks
DowDuPont, UC Davis team up to advance orphan African crops »

Dow AgroSciences teamed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADNT

Adient

$81.91

-0.51 (-0.62%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Downgrade
Adient rating change  »

Adient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

NTN

NTN Buzztime

$4.91

0.3 (6.51%)

, BWLD

Buffalo Wild Wings

$156.65

-0.1 (-0.06%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Hot Stocks
NTN Buzztime digital menu and payment go live at Buffalo Wild Wings »

NTN Buzztime (NTN), has…

NTN

NTN Buzztime

$4.91

0.3 (6.51%)

BWLD

Buffalo Wild Wings

$156.65

-0.1 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMMA

Alliance MMA

$0.87

0.04 (4.82%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Hot Stocks
Alliance MMA, FloSports announce event rights fee deal »

Alliance MMA announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSE

Trinseo

$77.45

-1.1 (-1.40%)

08:01
01/17/18
01/17
08:01
01/17/18
08:01
Recommendations
Trinseo analyst commentary  »

Trinseo price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$244.74

0.27 (0.11%)

08:01
01/17/18
01/17
08:01
01/17/18
08:01
Hot Stocks
3M submits 510(k) application for Attest 24-minute readout »

3M announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

LXFT

Luxoft

$55.35

-1.8 (-3.15%)

08:01
01/17/18
01/17
08:01
01/17/18
08:01
Upgrade
Luxoft rating change  »

Luxoft upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

DST

DST Systems

$83.63

0.12 (0.14%)

, SSNC

SS&C

$48.48

-0.99 (-2.00%)

08:00
01/17/18
01/17
08:00
01/17/18
08:00
Downgrade
DST Systems, SS&C rating change  »

DST Systems downgraded to…

DST

DST Systems

$83.63

0.12 (0.14%)

SSNC

SS&C

$48.48

-0.99 (-2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$17.16

-0.6 (-3.38%)

08:00
01/17/18
01/17
08:00
01/17/18
08:00
Options
GameStop put buyer realizes 26% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MON

Monsanto

$119.72

0.02 (0.02%)

08:00
01/17/18
01/17
08:00
01/17/18
08:00
Recommendations
Monsanto analyst commentary  »

Monsanto price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

08:00
01/17/18
01/17
08:00
01/17/18
08:00
General news
U.S. chain store sales fell 1.9% to 115.3 in the week ended January 13 »

U.S. chain store sales…

COG

Cabot Oil & Gas

$28.03

-0.85 (-2.94%)

07:59
01/17/18
01/17
07:59
01/17/18
07:59
Downgrade
Cabot Oil & Gas rating change  »

Cabot Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLK

Westlake Chemical

$110.40

-3.54 (-3.11%)

07:58
01/17/18
01/17
07:58
01/17/18
07:58
Recommendations
Westlake Chemical analyst commentary  »

Westlake Chemical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LADR

Ladder Capital

$14.62

1.03 (7.58%)

07:58
01/17/18
01/17
07:58
01/17/18
07:58
Hot Stocks
Ladder Capital reports unsolicited $15 per share takeover proposal from Related »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

LYB

LyondellBasell

$115.89

-1.79 (-1.52%)

07:57
01/17/18
01/17
07:57
01/17/18
07:57
Recommendations
LyondellBasell analyst commentary  »

LyondellBasell price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$163.35

-7.35 (-4.31%)

07:57
01/17/18
01/17
07:57
01/17/18
07:57
Technical Analysis
Technical Take: bluebird bio sharply higher in early trading »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.